RxDoctor Payments Data

John Davis, MD

Rheumatology · Rochester, MNNPI 1881665024

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $31,392 of the $32,467 with a category attached, or 96.7%. Pfizer accounts for 96.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $31,692 and has fallen 97.6% since, to $760 in 2025. Among rheumatology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,467in general payments, 2019–2025

Across 10 payments — averaging $3246.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$31K
  • Endologix LLC$708
  • Sanofi$301
  • Incyte Corporation$25
  • Tactile Systems Technology Inc$15
$98,328in research payments, 2019–2025

Across 20 payments — averaging $4916.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$98K

What the payments were for

  • Speaking & faculty fees$31,39297%
  • Travel & lodging$7082%
  • Food & beverage$3681%

General payments by program year

19
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,467 in reported general payments places this provider in the 90th percentile of 121 rheumatology providers in Minnesota.

See all rheumatology providers in Minnesota

Medicare billing

Part B allowed, 2024
$29,087
Medicare patients
153
Services billed
3,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IlarisCanakinumab/Pf13$242,883
RinvoqUpadacitinib19$149,562
Humira(Cf) PenAdalimumab18$119,883
KevzaraSarilumab19$111,251
Enbrel MiniEtanercept11$77,370
Hydroxychloroquine Sulfate35$1,474
MethotrexateMethotrexate Sodium37$1,184
Prednisone57$615
Colchicine17$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiKevzara$301$111,25119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 121 rheumatology providers in Minnesota.

Other rheumatology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →